Aliases & Classifications for Oppositional Defiant Disorder

MalaCards integrated aliases for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 76 55 6 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050856
ICD10 33 F91.3
UMLS 73 C0029121

Summaries for Oppositional Defiant Disorder

MalaCards based summary : Oppositional Defiant Disorder is related to separation anxiety disorder and depression, and has symptoms including sleep disturbances, photophobia and personality changes. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Oppositional defiant disorder (ODD) is defined by the DSM-5 as \"a pattern of angry/irritable mood,... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 separation anxiety disorder 30.5 DRD4 SLC6A3
2 depression 30.4 MAOA SLC6A4 TPH2
3 traumatic brain injury 29.8 COMT DRD2
4 brain injury 29.3 COMT DRD2
5 tic disorder 29.2 DRD2 DRD4 SLC6A3 TPH2
6 stuttering 29.1 DBH DRD2 SLC6A3
7 generalized anxiety disorder 29.0 DRD2 MAOA SLC6A2 SLC6A4
8 anxiety 28.8 COMT MAOA SLC6A2 SLC6A4 TPH2
9 borderline personality disorder 28.7 COMT MAOA SLC6A4 TPH2
10 gilles de la tourette syndrome 27.5 COMT DBH DRD2 DRD4 SLC6A3
11 conduct disorder 27.4 COMT DBH DRD2 DRD4 MAOA SLC6A3
12 autism 27.0 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
13 personality disorder 26.6 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
14 attention deficit-hyperactivity disorder 25.7 COMT DBH DRD2 DRD4 MAOA SLC6A2
15 alcohol dependence 25.1 COMT DBH DRD2 DRD4 MAOA SLC6A3
16 bipolar disorder 25.1 COMT DBH DRD2 DRD4 MAOA SLC6A3
17 schizophrenia 24.4 COMT DBH DRD2 DRD4 MAOA SLC6A2
18 dependent personality disorder 10.5 DRD4 MAOA
19 major affective disorder 1 10.4 SLC6A3 TPH2
20 atypical depressive disorder 10.4 MAOA SLC6A4
21 dysthymic disorder 10.4 MAOA SLC6A4
22 kleptomania 10.4 MAOA SLC6A4
23 delusional disorder 10.4 DRD2 DRD4
24 amphetamine abuse 10.4 SLC6A2 SLC6A3
25 impulse control disorder 10.3 DRD2 DRD4
26 striatonigral degeneration 10.3 DRD2 SLC6A3
27 heroin dependence 10.3 DRD2 DRD4
28 phobia, specific 10.2 COMT MAOA
29 aging 10.2
30 periodic limb movement disorder 10.2 DRD2 SLC6A4
31 bruxism 10.1 DRD2 SLC6A4
32 autism spectrum disorder 10.1
33 pseudobulbar affect 10.1
34 endogenous depression 10.1 MAOA SLC6A4
35 dystonia 1, torsion, autosomal dominant 10.1 COMT MAOA
36 schizophreniform disorder 10.0 COMT DRD2
37 polysubstance abuse 10.0 COMT DRD2
38 kleine-levin hibernation syndrome 10.0 COMT SLC6A3
39 tardive dyskinesia 10.0 COMT DRD2
40 fibromyalgia 10.0 COMT SLC6A4
41 orofacial cleft 10.0 DRD2 DRD4 SLC6A3
42 agoraphobia 10.0 MAOA SLC6A2 SLC6A4
43 restless legs syndrome 10.0 DRD2 MAOA SLC6A3
44 reading disorder 10.0
45 hematohidrosis 10.0
46 alcohol-induced mental disorder 9.9 DRD2 SLC6A3 SLC6A4
47 alcoholic psychosis 9.9 DRD2 SLC6A3 SLC6A4
48 autonomic nervous system disease 9.9 DBH DRD4
49 opioid addiction 9.9 COMT DRD2
50 migraine without aura 9.9 DRD2 DRD4 SLC6A4

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:



Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:


sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 MAOA SLC6A2 SLC6A3 COMT SLC6A4 DBH
2 homeostasis/metabolism MP:0005376 9.91 DRD4 MAOA SLC6A2 SLC6A3 COMT SLC6A4
3 cardiovascular system MP:0005385 9.87 MAOA SLC6A2 COMT SLC6A4 DBH TPH2
4 integument MP:0010771 9.63 SLC6A2 SLC6A3 SLC6A4 DBH TPH2 DRD2
5 nervous system MP:0003631 9.61 DRD4 MAOA SLC6A2 SLC6A3 COMT SLC6A4
6 taste/olfaction MP:0005394 8.8 SLC6A3 TPH2 DRD2

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
6
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
11 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
13 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
14 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Dopamine Antagonists Phase 4,Phase 3,Phase 2
16 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
19 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
20 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Serotonin Antagonists Phase 4,Phase 3,Phase 2
22 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Anticonvulsants Phase 4
24 Antimanic Agents Phase 4
25 GABA Agents Phase 4
26 Adrenergic Agents Phase 4,Phase 3
27 Atomoxetine Hydrochloride Phase 4,Phase 3
28 Autonomic Agents Phase 4
29 Peripheral Nervous System Agents Phase 4
30 Adrenergic Agonists Phase 4
31 Adrenergic alpha-2 Receptor Agonists Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Antihypertensive Agents Phase 4
34 Antiemetics Phase 4
35 Gastrointestinal Agents Phase 4
36 insulin Phase 4
37 Insulin, Globin Zinc Phase 4
38 Serotonin Uptake Inhibitors Phase 4
39 Lisdexamfetamine Dimesylate Phase 4
40
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
41
Ethanol Approved Phase 2, Phase 3,Phase 3 64-17-5 702
42
2-Phenylethanol Experimental Phase 2, Phase 3,Phase 3 60-12-8 6054
43 Antioxidants Phase 2, Phase 3
44 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable
45 Anti-Infective Agents Phase 2, Phase 3,Phase 3
46 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 3
47 Disinfectants Phase 2, Phase 3,Phase 3
48 Omega 3 Fatty Acid Nutraceutical Phase 2, Phase 3,Not Applicable
49 Pomegranate Nutraceutical Phase 2, Phase 3
50
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
4 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
5 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
6 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
7 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
8 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
9 Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Recruiting NCT02638168 Phase 4 Immediate Release Methylphenidate;Placebo
10 Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Recruiting NCT02951754 Phase 4 Immediate-release Methylphenidate
11 Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention Recruiting NCT03279952 Phase 4 CNS Stimulant
12 Omega-3 Supplementation and Behavior Problems Unknown status NCT02334098 Phase 2, Phase 3
13 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Completed NCT00192023 Phase 3 atomoxetine 0.5 mg/kg/day;placebo;atomoxetine 1.2 mg/kg/day;atomoxetine 1.2-1.4 mg/kg/day
14 Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Completed NCT00191698 Phase 3 atomoxetine hydrochloride;placebo
15 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
16 Strongest Families Ontario (Formerly the Family Help Program) Completed NCT01473511 Phase 3
17 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
18 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
19 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
20 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
21 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
22 Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Completed NCT00402857 Phase 3
23 Brief Strategic Family Therapy for Adolescent Drug Abusers Completed NCT00095303 Phase 3
24 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
25 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00320528 Phase 3 atomoxetine
26 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
27 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
28 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
29 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior. Completed NCT00550147 Phase 2 Oros Methylphenidate;quetiapine
30 Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01725737 Phase 2 GlyTI-M;Placebo
31 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
32 Treatment of Conduct Problems and Depression Unknown status NCT01267773 Phase 1
33 Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
34 Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189 Not Applicable
35 Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986 Not Applicable
36 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
37 Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children Unknown status NCT02433145
38 Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT01330849 Not Applicable
39 Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder Completed NCT03447535
40 Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Completed NCT00510120 Not Applicable
41 Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Completed NCT00404911 Not Applicable
42 On-line Treatment for Conduct Problems Completed NCT01822392 Not Applicable
43 Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits Completed NCT01362946 Not Applicable
44 Supplements and Social Skills Intervention Study Completed NCT00819429 Not Applicable
45 Evaluating the Feasibility of Internet-delivered PCIT Completed NCT03260725 Not Applicable
46 Resources to Enhance the Adjustment of Children (REACH) Completed NCT00820001 Not Applicable
47 The Effectiveness of Parent-Child Interaction Therapy (PCIT) Completed NCT01085305 Not Applicable
48 School-Based Mental Health Services for Urban Children Completed NCT00612690 Not Applicable
49 Correlating Real and Virtual World Behavioral Fluctuations in Adolescence Completed NCT02281825
50 Brain Changes in Children and Adolescents With Behavioral Problems Completed NCT00104039

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

41
Brain, Testes, Cortex, Eye

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 152)
# Title Authors Year
1
The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. ( 29958238 )
2018
2
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
3
Social skills training and play group intervention for children with oppositional-defiant disorders/conduct disorder: Mediating mechanisms in a head-to-head comparison. ( 29347904 )
2018
4
Junior temperament character inventory together with quantitative EEG discriminate children with attention deficit hyperactivity disorder combined subtype from children with attention deficit hyperactivity disorder combined subtype plus oppositional defiant disorder. ( 29787785 )
2018
5
Child-based treatment of oppositional defiant disorder: mediating effects on parental depression, anxiety and stress. ( 29948233 )
2018
6
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
7
Maltreatment and Affective and Behavioral Problems in Emerging Adults With and Without Oppositional Defiant Disorder Symptoms: Mediation by Parent-Child Relationship Quality. ( 29528803 )
2018
8
Structural Brain Abnormalities of Attention-Deficit/Hyperactivity Disorder With Oppositional Defiant Disorder. ( 28911901 )
2017
9
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial. ( 28213188 )
2017
10
The Mutual Effect of Marital Quality and Parenting Stress on Child and Parent Depressive Symptoms in Families of Children with Oppositional Defiant Disorder. ( 29104548 )
2017
11
Predictors of Partial Hospital Readmission for Young Children with Oppositional Defiant Disorder. ( 29164350 )
2017
12
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
13
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. ( 28398816 )
2017
14
Sex differences in the associations between vagal reactivity and oppositional defiant disorder symptoms. ( 28573761 )
2017
15
The Characteristics and Age Effects of Emotional Lability in ADHD Children With and Without Oppositional Defiant Disorder. ( 29224418 )
2017
16
Family and Individual Risk and Protective Factors of Depression among Chinese Migrant Children with Oppositional Defiant Disorder Symptoms. ( 28421024 )
2017
17
Age 4 Predictors of Oppositional Defiant Disorder in Early Grammar School. ( 28278601 )
2017
18
Parental involvement as an etiological moderator of middle childhood oppositional defiant disorder. ( 28263622 )
2017
19
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
20
Comparing the characteristics and outcomes of parent- and teacher-reported oppositional defiant disorder: findings from a national sample. ( 29230806 )
2017
21
Oppositional defiant disorder: current insight. ( 29238235 )
2017
22
Multi-Level Family Factors and Affective and Behavioral Symptoms of Oppositional Defiant Disorder in Chinese Children. ( 28713321 )
2017
23
Is emotional dysregulation a risk indicator for auto-aggression behaviors in adolescents with oppositional defiant disorder? ( 27764737 )
2017
24
Oppositional defiant disorder dimensions: genetic influences and risk for later psychopathology. ( 28059443 )
2017
25
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( 28806385 )
2017
26
Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder. ( 28283834 )
2017
27
Testing Multiple Conceptualizations of Oppositional Defiant Disorder in Youth. ( 28287828 )
2017
28
Executive Function Features in Drug-naive Children with Oppositional Defiant Disorder. ( 28955142 )
2017
29
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
30
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2016
31
Trait and State Variance in Oppositional Defiant Disorder Symptoms: A Multi-Source Investigation With Spanish Children. ( 27148784 )
2016
32
Child Personality Accounts for Oppositional Defiant Disorder Comorbidity Patterns. ( 27233508 )
2016
33
Emotional Regulation and Executive Function Deficits in Unmedicated Chinese Children with Oppositional Defiant Disorder. ( 27247593 )
2016
34
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
35
Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis. ( 27282758 )
2016
36
Common Questions About Oppositional Defiant Disorder. ( 27035043 )
2016
37
Association of tryptophan hydroxylase-2 polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 27871272 )
2016
38
The Reciprocal Influence of Callous-Unemotional Traits, Oppositional Defiant Disorder and Parenting Practices in Preschoolers. ( 27013514 )
2016
39
The Longitudinal Effects of Oppositional Defiant Disorder Symptoms on Academic and Occupational Functioning in the Transition to Young Adulthood. ( 27469319 )
2016
40
Innocent or Intentional?: Interpreting Oppositional Defiant Disorder in a Preschool Mental Health Clinic. ( 27761690 )
2016
41
Is Emotional Lability Distinct From &amp;quot;Angry/Irritable Mood,&amp;quot; &amp;quot;Negative Affect,&amp;quot; or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2016
42
Multiple Levels of Family Factors and Oppositional Defiant Disorder Symptoms Among Chinese Children. ( 27900762 )
2016
43
Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children. ( 27443598 )
2016
44
A Systematic Review and Meta-analysis of Neuroimaging in Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD) Taking Attention-Deficit Hyperactivity Disorder (ADHD) Into Account. ( 26846227 )
2016
45
Early development of comorbidity between symptoms of attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD). ( 26854502 )
2016
46
The role of anxiety in cortisol stress response and cortisol recovery in boys with oppositional defiant disorder/conduct disorder. ( 27521740 )
2016
47
Memory consolidation of socially relevant stimuli during sleep in healthy children and children with attention-deficit/hyperactivity disorder and oppositional defiant disorder: What you can see in their eyes. ( 28049026 )
2016
48
Preschool Oppositional Defiant Disorder: A Disorder of Negative Affect, Surgency, and Disagreeableness. ( 27768388 )
2016
49
Oral health status, dental anxiety, and behavior-management problems in children with oppositional defiant disorder. ( 26707341 )
2016
50
Emotion Socialization in the Context of Risk and Psychopathology: Maternal Emotion Coaching Predicts Better Treatment Outcomes for Emotionally Labile Children with Oppositional Defiant Disorder. ( 26848211 )
2016

Variations for Oppositional Defiant Disorder

ClinVar genetic disease variations for Oppositional Defiant Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(2;11)(q31;q13.5)pat Translocation Uncertain significance
2 46;XY;t(4;7)(q31;q22)dn Translocation Uncertain significance
3 46;XX;t(2;5)(q33;p15.3) Translocation Uncertain significance

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 COMT MAOA SLC6A3 SLC6A4
2
Show member pathways
12.67 COMT DRD2 DRD4 MAOA SLC6A3
3 12.29 COMT DBH TPH2
5 11.92 MAOA SLC6A4 TPH2
6 11.86 SLC6A2 SLC6A3 SLC6A4
7
Show member pathways
11.72 DRD2 MAOA SLC6A3
8 11.69 MAOA SLC6A4 TPH2
9
Show member pathways
11.51 COMT SLC6A2 SLC6A4
10
Show member pathways
11.43 COMT DBH MAOA
11
Show member pathways
11.17 DBH TPH2
12 10.91 DBH SLC6A2
13 10.88 MAOA SLC6A4 TPH2
14
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
15
Show member pathways
10.69 COMT MAOA
16
Show member pathways
10.67 COMT DBH MAOA
17
Show member pathways
10.67 COMT MAOA SLC6A3 SLC6A4
18 10.64 COMT MAOA

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.65 DRD2 DRD4 SLC6A2 SLC6A3 SLC6A4
2 integral component of membrane GO:0016021 9.56 COMT DBH DRD2 DRD4 MAOA SLC6A2
3 axon GO:0030424 9.5 COMT DRD2 SLC6A3
4 membrane raft GO:0045121 9.33 SLC6A2 SLC6A3 SLC6A4
5 neuron projection GO:0043005 8.92 SLC6A2 SLC6A3 SLC6A4 TPH2

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.77 COMT DRD2 SLC6A2 SLC6A3 SLC6A4
2 locomotory behavior GO:0007626 9.7 DBH DRD2 SLC6A3
3 social behavior GO:0035176 9.65 DRD4 SLC6A4
4 visual learning GO:0008542 9.65 DBH DRD2
5 response to nicotine GO:0035094 9.65 DRD2 SLC6A3
6 response to cocaine GO:0042220 9.64 DRD2 SLC6A3
7 positive regulation of multicellular organism growth GO:0040018 9.64 DRD2 SLC6A3
8 associative learning GO:0008306 9.63 DBH DRD2
9 arachidonic acid secretion GO:0050482 9.63 DRD2 DRD4
10 neurotransmitter transport GO:0006836 9.63 SLC6A2 SLC6A3 SLC6A4
11 behavioral response to cocaine GO:0048148 9.62 DRD2 DRD4
12 dopamine receptor signaling pathway GO:0007212 9.62 DRD2 DRD4
13 response to iron ion GO:0010039 9.61 DRD2 SLC6A3
14 negative regulation of protein secretion GO:0050709 9.61 DRD2 DRD4
15 response to amphetamine GO:0001975 9.61 DBH DRD2 DRD4
16 neurotransmitter biosynthetic process GO:0042136 9.6 SLC6A3 SLC6A4
17 negative regulation of voltage-gated calcium channel activity GO:1901386 9.59 DRD2 DRD4
18 prepulse inhibition GO:0060134 9.58 DRD2 SLC6A3
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD4
20 response to pain GO:0048265 9.58 COMT DBH SLC6A2
21 neurotransmitter catabolic process GO:0042135 9.57 COMT MAOA
22 catecholamine metabolic process GO:0006584 9.56 COMT MAOA
23 regulation of dopamine metabolic process GO:0042053 9.55 DRD4 SLC6A3
24 adenohypophysis development GO:0021984 9.54 DRD2 SLC6A3
25 fear response GO:0042596 9.51 DBH DRD4
26 behavioral response to ethanol GO:0048149 9.5 DBH DRD2 DRD4
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.49 DRD2 DRD4
28 response to histamine GO:0034776 9.48 DRD2 DRD4
29 dopamine metabolic process GO:0042417 9.43 COMT DRD2 DRD4
30 monoamine transport GO:0015844 9.33 SLC6A2 SLC6A3 SLC6A4
31 dopamine uptake involved in synaptic transmission GO:0051583 9.13 SLC6A2 SLC6A3 SLC6A4
32 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transporter activity GO:0005215 9.63 SLC6A2 SLC6A3 SLC6A4
2 symporter activity GO:0015293 9.61 SLC6A2 SLC6A3 SLC6A4
3 drug binding GO:0008144 9.54 DRD2 DRD4 SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A2 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD4
6 dopamine binding GO:0035240 9.33 DRD2 DRD4 SLC6A3
7 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD4
8 monoamine transmembrane transporter activity GO:0008504 9.13 SLC6A2 SLC6A3 SLC6A4
9 dopamine:sodium symporter activity GO:0005330 8.8 SLC6A2 SLC6A3 SLC6A4
10 metal ion binding GO:0046872 10.02 COMT DBH DRD4 SLC6A2 SLC6A3 SLC6A4

Sources for Oppositional Defiant Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....